Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 51 | 1 | 73 | +23 |
| Shares | 13.2M | 1.31K | 20.0M | +6.77M (+51.3%) |
| Value | $222.2M | $22.0K | $291.7M | +$69.5M (+31.3%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (24)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (1)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| DLD Asset Management, LP | 32,500 | $547.0K |
Not filed for Q2 2022 yet (1)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 1,306 | $22.0K |